| Description | Teplizumab (MGA-031) is a humanized monoclonal antibody against CD3 that slows the loss of beta cell function.Teplizumab is used to treat type 1 diabetes. |
| In vitro | Teplizumab通过在10 ng/mL至10 μg/mL的浓度下，5天内诱导人类CD8+ T细胞增殖[3]。同时，经过6天处理，Teplizumab能增加新鲜分离的PBMCs中CD8+细胞表面CD25的表达以及细胞内CTLA4的水平[2]。 |
| In vivo | 在NSG小鼠中，Teplizumab（0.24 mg/kg，i.p.）可诱导人类CD4 T细胞向黏膜下层迁移，并消除该药物对移植物存活的治疗效果[3]。 |
| Synonyms | PRV-031, MGA-031 |
| molecular weight | N/A |
| CAS | 876387-05-2 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. 2. Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13. 3. Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12. |